2,3-二氢-1,4-苯并二噁英-5-甲腈 | 148703-14-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 2,3-二氢-1,4-苯并二噁英-5-甲腈
• 中文别名: 苯并二氧六环-5-甲腈
• 英文名称: 2,3-dihydro-benzo[1,4]dioxin-5-carbonitrile
• 英文别名: 2,3-Dihydro-1,4-benzodioxine-5-carbonitrile
• CAS: 148703-14-4
• 化学式: C₉H₇NO₂
• 分子量: 161.16
• InChiKey: WNNQCWLSQDNACP-UHFFFAOYSA-N

物化性质

• 熔点：
  51.5-52.0 °C
• 沸点：
  127-129 °C(Press: 1 Torr)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  42.2
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P260,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,3-Dihydro-1,4-benzodioxine-5-carbonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,3-Dihydro-1,4-benzodioxine-5-carbonitrile
CAS number: 148703-14-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H7NO2
Molecular weight: 161.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氢-1,4-苯并二噁英-5-甲腈 在 乙醚 、 乙基溴化镁 作用下， 生成 1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-propan-1-one
  参考文献：
  名称：

  REPLACEMENT OF NUCLEAR ALKOXYL GROUPS BY THE ACTION OF GRIGNARD REAGENTS

  摘要：

  DOI：

  10.1021/jo01162a005
• 作为产物：
  描述：

  2,3-二氢-1,4-苯并二恶烷-5-羰酰氯 在 ammonium hydroxide 、 氯化亚砜 、 苯 作用下， 生成 2,3-二氢-1,4-苯并二噁英-5-甲腈
  参考文献：
  名称：

  REPLACEMENT OF NUCLEAR ALKOXYL GROUPS BY THE ACTION OF GRIGNARD REAGENTS

  摘要：

  DOI：

  10.1021/jo01162a005

文献信息

• [EN] OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES<br/>[FR] ANTAGONISTES DES RÉCEPTEURS DE L'OREXINE, QUI SONT DES DÉRIVÉS [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014057435A1

  公开（公告）日：2014-04-17

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式(I)中的[ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-甲酮衍生物，其中R和环A1、A2和A3如描述中所述，以及其药用盐，其制备方法，含有一个或多个公式(I)化合物的药物组合物，以及它们作为药物的用途，特别是作为促进睡眠荷尔蒙受体拮抗剂的用途。
• Novel heteroaryl derivatives, their preparation and use
  申请人：H. Lundbeck A/S

  公开号：US20030050306A1

  公开（公告）日：2003-03-13

  A heteroaryl derivative having the formula (I) 1 any of its enantiomers or any mixture thereof, wherein X is —O—, —S—, or CR 4 R 5 —; and Y is —CR 6 R 7 ; —CR 6 R 7 —CR 8 R 9 —, or —CR 6 —CR 7 ; or X and Y together form a group —CR 4 ═R 5 —, or —CR 4 ═CR 5 —CR 6 R 7 —; Z is —O—, or —S—; W is N, C, or CH; n is 2, 3, 4, 5, 6, 7, 8, 9 or 10; m is 2 or 3; A is O or S wherein the doted lines mean an optional bond. The compounds of the invention are considered useful for the treatment of affective disorders such as general anxiety disorder, panic disorder, obsessive compulsive disorder, depression, social phobia and eating disorders, and neurological disorders such as psychosis.

  具有以下结构式(I)的杂环芳基衍生物，其中X为—O—、—S—或CR4R5—；Y为—CR6R7、—CR6R7—CR8R9—或—CR6—CR7；或者X和Y一起形成一个基团—CR4═R5—或—CR4═CR5—CR6R7—；Z为—O—或—S—；W为N、C或CH；n为2、3、4、5、6、7、8、9或10；m为2或3；A为O或S，其中点线表示可选键。该发明的化合物被认为对治疗情感障碍，如广泛性焦虑障碍、恐慌障碍、强迫症、抑郁症、社交恐惧症和进食障碍，以及神经症如精神病等是有用的。
• OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20150252032A1

  公开（公告）日：2015-09-10

  The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives of formula (I) wherein R, and the rings A 1 A 2 and A 3 are as described in the description, to pharmaceutically acceptable salts thereof, to their preparation, to pharmaceutical compositions containing one or more compounds of formula (I), and to their use as pharmaceuticals, especially to their use as orexin receptor antagonists.

  本发明涉及公式（I）的[ortho bi-（hetero-）aryl]-[2-（meta bi-（hetero-）aryl）-pyrrolidin-1-yl]-methanone衍生物，其中R和环A1A2和A3如描述中所述，以及其药学上可接受的盐、其制备方法、含有一个或多个公式（I）化合物的制药组合物以及它们作为药物的用途，特别是作为促进睡眠激素受体拮抗剂的用途。
• 10.1055/a-2331-2707
  作者：Wilson, Nicolas A.、Palmer, William M.、Ganley, Jacob M.、Coombs, John R.、Levorse, Mark S.、Albaneze-Walker, Jennifer、Frantz, Doug E.

  DOI：10.1055/a-2331-2707

  日期：——

  conversion of phenols into benzonitriles via aryl imidazolylsulfonates with a non-toxic cyanide source, potassium ferrocyanide, has been developed. Salient features of this method include low palladium precatalyst loadings (as low as 1.0 mol% total Pd), mild reaction conditions, and environmentally benign by-products compared to other (pseudo)halide aryl electrophiles. The initial scope of the reaction

  已经开发出一种通用的钯催化方法，通过芳基咪唑基磺酸盐与无毒的氰化物源亚铁氰化钾将苯酚转化为苯酚。与其他（拟）卤化芳基亲电子试剂相比，该方法的显着特点包括钯预催化剂负载量低（总钯含量低至 1.0 mol%）、温和的反应条件以及对环境无害的副产物。演示了一系列酚类前体反应的初始范围，包括将酚直接转化为苯甲腈的一锅两步方法。
• NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE
  申请人：H. LUNDBECK A/S

  公开号：EP1246820A1

  公开（公告）日：2002-10-09